Form 4: Soleno Therapeutics Executive Patricia Hirano Reports Stock Sales and Option Exercises

Patricia Hirano, a Senior Vice President at Soleno Therapeutics, reported the sale of common stock to cover tax obligations and the exercise of employee stock options.

Summary

• On March 27 and 28, 2025, Patricia Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics, engaged in multiple transactions involving the company's common stock.
• These transactions included the sale of shares to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
• Hirano also exercised employee stock options to acquire shares at prices ranging from $2.41 to $33.60.
• The sales of common stock were executed at prices ranging from approximately $65.15 to $73.60 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these transactions, Hirano directly owns 30,818 shares of Soleno Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely minimal given the volume of shares traded.

Key Dates

Keywords

Form 4, insider trading, stock options, restricted stock units, Rule 10b5-1, Patricia Hirano, Soleno Therapeutics, SLNO, stock sales